Home > NASDAQ: STEM, SC Proven product Portfolio, Stem Cell Research > StemCells (STEM) adds to SC Proven Portfolio

StemCells (STEM) adds to SC Proven Portfolio

STEM launched 3 new cell culture supplements for the derivation, culture and differentiation of human and mouse embryonic stem (ES) cells, induced pluripotent stem (iPS) cells and tissue-derived neural stem (NS) cells.

The use of animal component-free formulations is an important consideration for researchers considering bench-to-bedside applications in which human stem cell lines may be derived, expanded and banked for potential future translation into clinical trials.

  • NDiff(R) N2-AF is a proprietary, defined, serum-free and animal component-free version of NDiff N2 product, a proprietary, defined, serum-free cell culture supplement based on the original Bottenstein formulation;
  • NDiff N27 is a proprietary, defined, serum-free cell culture supplement based on the original Brewer formulation;
  • NDiff N27-AF is a proprietary, defined, serum-free and animal component-free version of NDiff N27.

The Bottom Line: Expanding lines of SC Proven cell culture supplements provides researchers with well-defined reagents that are free of the serum and animal protein-derived contaminants that can cause variability of performance and impair analyses, particularly in the context of stem cell-based drug screens. These new lines satisfy this demand by providing researchers with additional choices to use either a defined, serum-free, or a defined, serum-free and animal component-free (AF) version. The SC Proven product portfolio comprises a range of products for the detection, isolation, expansion, differentiation, and characterization of a variety of different human and animal cell types. In 2010, SC Proven product sales revenue grew by approximately 30%, and continues double digit growth.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • StumbleUpon
  • Reddit
  • Facebook
  • LinkedIn
  • TwitThis
  1. No comments yet.
  1. No trackbacks yet.